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Background: Cisplatin, a powerful antitumor agent, causes formation of DNA adducts,
and activation of apoptotic pathways. Presently, cisplatin resistance develops in up
to 70% of patients but the underlying molecular mechanism(s) are unclear and there
are no markers to determine which patients will become resistant. Mitochondria
play a significant role not only in energy metabolism but also retrograde signaling
(mitochondria to nucleus) that modulates inflammation, complement, and apoptosis
pathways. Maternally inheritedmitochondrial (mt) DNA can be classified into haplogroups
representing different ethnic populations that have diverse susceptibilities to diseases
and medications.
Methods: Transmitochondrial cybrids, where all cell lines possess identical nuclear
genomes but either the H (Southern European) or J (Northern European) mtDNA
haplogroups, were treated with cisplatin and analyzed for differential responses related
to viability, oxidative stress, and expression levels of genes associated with cancer,
cisplatin-induced nephrotoxicity and resistance, apoptosis and signaling pathways.
Results: The cisplatin-treated-J cybrids showed greater loss of cell viability along with
lower levels of reactive oxygen species and mitochondrial membrane potential compared
to cisplatin-treated-H cybrids. After cisplatin treatment, J cybrids showed increased
gene expression of BAX, CASP3, and CYP51A, but lower levels of SFRP1 compared
to untreated-J cybrids. The cisplatin-treated-H cybrids had elevated expression of
CDKN1A/P21, which has a role in cisplatin toxicity, compared to untreated-H cybrids.
The cisplatin-treated H had higher transcription levels of ABCC1, DHRS2/HEP27, and
EFEMP1 compared to cisplatin-treated-J cybrids.
Conclusions: Cybrid cell lines that contain identical nuclei but either H mtDNA
mitochondria or J mtDNA mitochondria respond differently to cisplatin treatments
Patel et al. Response to Cisplatin Is Influenced by mtDNA Variants
suggesting involvement of the retrograde signaling (from mitochondria to nucleus) in the
drug-induced cell death. Varying toxicities and transcription levels of the H vs. J cybrids
after cisplatin treatment support the hypothesis that mtDNA variants play a role in the
expression of genes affecting resistance and side effects of cisplatin.
Keywords: cisplatin, mitochondria, cybrids, drug resistance, mtDNA haplogroups
INTRODUCTION
Cisplatin is a non-specific alkylating agent used for decades
to successfully treat various cancers. However, cisplatin has
dose-dependent toxicity and resistance often develops (1, 2).
Mitochondrial dynamics play an important role in resistance
to chemotherapy and severity of side effects. Many anti-cancer
medications can cause mitochondrial dysfunction and DNA
damage, and cells depleted of mtDNA show increased resistance
to chemotherapeutic agents. Cisplatin is a pro-apoptotic drug
that damages mitochondria, contributing to the toxicities in
gastrointestinal, auditory, and kidney proximal tubule cells (3–5).
Cisplatin treatment of head and neck squamous cell carcinoma
and Chinese hamster ovarian cells significantly increases adduct
formation in mitochondrial (mt) DNA compared to nuclear
(n) DNA (6). Furthermore, mtDNA is more likely to remain
damaged after cisplatin exposure because mitochondria lack the
nucleotide-excision repair mechanisms found in nDNA. The
severity of cancer drug side effects and incidence of induced
resistance to chemotherapy drugs vary amongst individuals but
the mechanism(s) are still not fully understood.
Cisplatin side effects include nausea, vomiting,
myelosuppression, nephrotoxicity, neurotoxicity, cognitive
dysfunction retinopathy, and hearing loss. Intravenous delivery
of cisplatin commonly causes mild to moderate pigmentary
retinopathy, along with intra-retinal hemorrhages, exudates,
and cotton wool spots (7). In addition, significant vision loss
can occur with both systemic and local delivery methods of the
drug (7). However, it is unclear which individuals are going to
be susceptible to this toxicity. The decision to continue a drug
regimen depends not only on the effectiveness in treating the
malignancy, but also on a person’s tolerance to the drug and the
risks of end-organ damage. Thus, insight into the mechanisms
of cisplatin toxicity is valuable to patient care and therefore, a
model using human retinal pigment epithelial (RPE) cells was
developed to study mechanisms of cytotoxic damage.
Mitochondria are unique organelles that play essential roles
in ATP production, calcium homeostasis, apoptosis, and cell
signaling. The mtDNA are maternally inherited and can be
classified into different haplogroups based on patterns of
single nucleotide polymorphisms (SNPs) that have accumulated
over thousands of years. The mtDNA haplogroups represent
populations from different geographic origins and subsequently,
can be used to characterize different ethnic groups. Clinically,
different ethnic populations show dissimilar susceptibilities to
diseases and drug responses (8–10), and it has been suggested
that mtDNA haplogroups may play important roles in these
differences (11). Specific mtDNA haplogroups have also been
associated with renal, prostate, breast, and lung cancers (12–15).
In addition, somatic and germline mtDNA mutations, as well
as levels of mtDNA copy numbers, have been associated with
increased risk of cancer and different responses to anti-cancer
drugs (16). These studies demonstrate how polymorphisms
and/or variants in mtDNA can lead to significant changes at the
molecular and cellular levels and can be associated with increased
cancer risk.
One method to characterize the functional consequences
of cells having specific mtDNA haplogroups is through
transmitochondrial cybrids (cells with identical nuclei but
different mtDNA). Previously, we demonstrated that H cybrids
(Southern European maternal origin mtDNA) vs. J cybrids
(Northern European maternal origin mtDNA) have significantly
different cellular homeostasis. Although all cybrids had identical
nuclei and culture conditions, cells containing the J mtDNA had
increased rates of growth along with higher lactate and glycolysis
levels, but showed significantly lower MT-RNA expression and
ATP levels compared to the H cybrids (17, 18). Interestingly,
even though the J cybrids were created in a non-cancerous
human retinal cell line (ARPE-19), the behavior of these cells was
characteristic of the Warburg Effect, which described cancerous
cells to be more glycolytic, using less oxidative phosphorylation,
and producing high amounts of lactate in the presence of oxygen
(aerobic glycolysis).
Using a HeLa cybrid model, Amo et al. was able to
demonstrate that resistance to cisplatin was conferred via
alterations of the mtDNA within the control region and that
cisplatin-resistant clones possessed shorter OriB variants within
a 16184-16193 region enriched with cytosine repeats (19).
Interestingly, alterations of the nuclear genomewere not involved
in the cisplatin resistance. These findings support the hypothesis
that the SNP differences that define the different haplogroups
would be important for the responses to cisplatin and as the H
and J haplogroup populations possess disparate SNP patterns,
then their cybrids would show different responses.
In the present study, we compared the effects of cisplatin on
human RPE cell cybrids that possessed either H or J haplogroup
mtDNA and found differential responses in levels of cell viability,
reactive oxygen species production, mitochondrial membrane
potential, and gene expression levels in pathways related to cell
signaling, apoptosis, and cisplatin resistance.
METHODS
Cybrid Creation
All subjects read and signed an informed consent (IRB #2003-
3131) from the Institutional Review Board of the University
of California, Irvine. All clinical investigations and protocols
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TABLE 1A | SNPs found by NGS in J Haplogroup Cybrids.
Loci: MT- SNP AA Change Locus rs# CY 10-01 CY 10-05 CY 11-32 CY 12-43 CY 13-62 CY 13-74 CY 13-107
CR:HV2/OHR 152 T>C NonCoding rs117135796 J1d
CR:HV2/OHR 185 G>A NonCoding na J1c J1c
CR:HV2/OHR 200 A>G NonCoding rs372099630 8.28%
Htroplsmy
CR:HV2/OHR 228 G>A NonCoding rs41323649 J1c J1c J1c
CR:HV2/OHR 242 C>T NonCoding na J1b1a
CR:HV2/OHR 271 C>T NonCoding na J1b1b
CR:HV2/OHR 295 C>T NonCoding rs41528348 J J J J J J J
CR:HV3 462 C>T NonCoding rs41402146 J1 J1 J1 J1 J1 J1 J1
CR:HV3 482 T>C NonCoding rs386419941 J1c1 J1c1
CR:HV3 489 T>C NonCoding rs28625645 J J J J J J J
tRNA Phe 596 T>C tRNA na 5.4%
Htroplsmy
RNR1 1007 G>A rRNA rs111033213 J1d1a
RNR2 2158 T>C rRNA rs41349444 J1b1a
RNR2 2305 T>C Unique na PVT-b
RNR2:Hum 2655 G>A Unique na 7.95%
Htroplsmy
RNR2 3010 G>A rRNA rs3928306 J1 J1 J1 J1 J1 J1 J1
RNR2 3197 T>C rRNA rs2854131 6.79%
Htroplsmy
TER/TL1 3242 G>A tRNA rs193303018 17.29%
Htroplsmy
ND1 3394 T>C Tyr30His rs41460449 J1c1 J1c1
ND1 3847 T>C Syn:Leu181 na PVT-a
ND1 4216 T>C Tyr304His rs1599988 JT JT JT JT JT JT JT
ND2 5460 G>A Ala331Thr rs3021088 J1b1 J1b1
tRNA Cys 5821 G>A tRNA rs200587831 3.44%
Htroplsmy
CO1 6261 G>A Ala120Thr rs201262114 PVT-a
CO1 6554 C>T Syn:Thr217 na J1c7
CO1 6734 G>A Syn:Met277 rs41413745 PVT-b
CO1 6899 G>A Syn:Met332 na PVT-b
CO1 7146 A>G Thr415Ala rs372136420 3.25%
Htroplsmy
CO1 7226 G>A Syn:Ser441 rs369835151 PVT-b
CO1 7256 C>T Syn:Asn451 rs41542322 4.2%
Htroplsmy
3.1%
Htroplsmy
CO2 7747 C>T Syn:Asn54 rs28608702 J1b1b1c
CO2 7789 G>A Syn:Leu68 rs386829014 J1d
(Continued)
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TABLE 1A | Continued
Loci: MT- SNP AA Change Locus rs# CY 10-01 CY 10-05 CY 11-32 CY 12-43 CY 13-62 CY 13-74 CY 13-107
CO2 7805 G>A Val74Ile na PVT-b
CO2 7963 A>G Syn:Leu126 na J1d
CO2 8192 A>G Asn203Tyr na 3.24%
Htroplsmy
CO2 8200 T>C Syn:Ser205 na PVT-b
CO2 8269 G>A Syn:Ter228 na J1b J1b J1b
ATP8/ATP6 8557 G>A Syn:Leu64/Ala11Thr rs386829040 J1b1a
CO3 9635 A>C Syn:Ser143 na J1c1a
ND3 10398 A>C Thr114Ala rs2853826 J J J J J J J
tRNA Arg 10410 T>A tRNA rs200478835 J1b1b1
ND4L 10654 C>T Ala62Val na PVT-b
ND4 11251 A>G Syn:Leu164 rs3915952 JT JT JT JT JT JT JT
ND4 11623 C>T Syn:Tyr288 na J1c1a
ND4 11827 T>C Syn:Ala356 rs368026942 10.16%
Htroplsmy
ND4 12007 G>A Syn:Trp416 rs2853497 J1b1a
ND4 12127 G>A Syn:Gly456 na J1c7
ND5 12612 A>G Syn:Val92 rs28359172 J J J J J J J
ND5 13143 T>C Syn:Asn269 rs386829174 PVT-b
ND5 13708 G>A Ala458Thr rs28359178 J J J J J J J
ND5 13879 T>C Ser515Pro rs200380057 J1b1 J1b1
ND5 13899 T>C Syn:Tyr521 rs370031192 J1c1a
ND6 14028 A>G Syn:Lys564 na PVT-b
CYB 14798 T>C Phe18Leu rs28357681 J1c J1c J1c
CYB 15452 C>A Leu236Ile rs527236209 JT JT JT JT JT JT JT
CYB 15769 A>G Syn:Gln341 na 4.9%
Htroplsmy
CR:HV1 16069 C>T NonCoding rs147903261 J J J J J J J
CR:TAS2 16092 T>C NonCoding na J1c7
CR:TAS2 16126 T>C NonCoding rs147029798 JT JT JT JT JT JT JT
CR:7SDNA 16145 G>A NonCoding rs41419246 J1b J1b J1b
CR:HV1 16193 C>T NonCoding na J1d
CR:HV1 16209 T>C NonCoding rs386829278 PVT-b
CR:HV1 16222 C>T NonCoding rs386829282 J1b
CR:HV1 16261 C>T NonCoding rs138126107 J1b J1b J1b
CR:HV1 16263 T>A NonCoding rs386829294 J1c7 PVT-a
CR:HV1 16292 C>T NonCoding rs144417390 PVT-a
CR:HV1 16300 A>G NonCoding na J1d1
CR:HV1 16309 A>G NonCoding rs373517769 J1d1a
PVT-a, found in other J or H haplogroups.
PVT-b, not found in other J or H haplogroups.
na:, not available.
All SNP’s had a Quality (A Phred-scaled quality score assigned by the variant caller) Score of 100 and PASSed all the Filters.
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were conducted according to the principles of the Declaration of
Helsinki and approved by the appropriate investigational review
boards (University of California, Irvine). Cybrids were generated
as described previously (17, 18). H and J cybrids were created by
polyethylene glycol fusion of platelets with the Rho0 (mtDNA
free) ARPE-19 cells, which had been treated by low dosage
ethidium bromide as described by Miceli and Jazwinski (20). H
and J cybrids were cultured to the fifth passage using DMEM-
F12 containing 10% dialyzed fetal bovine serum, 100 unit/ml
penicillin and 100µg/ml streptomycin, 2.5µg/ml fungizone,
50µg/ml gentamycin, and 17.5mM glucose. Figure 1 provides
description of the background of the subjects used in this study.
The ages for the H mtDNA subjects (n = 7 cybrids) were 30.57
± 3.39 years old, while ages for the J mtDNA subjects (n = 7
cybrids) were 36.14 ± 5.47 years (P = 0.4) (Figure 1A). There
were 4 males and 3 females for the J haplogroup subjects and 5
males and 2 females in the H haplogroup subjects. Figures 1B,C
show the haplogroup defining SNPs in the mtDNA for the
J cybrids and H cybrids used in this study (see sequencing
method below).
Sequencing of mtDNA From H and
J Cybrids
DNA was extracted from the individual cybrids (n = 7 for H
cybrids and n = 7 for J cybrids) using a kit (DNeasy Blood
and Tissue Kit, Qiagen, Germantown, MD). Next Generation
Sequencing (NGS) technology that sequences both strands of
mtDNA independently in both directions was used to quantitate
the haplogroup-defining SNPs, private SNPs (not defining
haplogroups), and low frequency heteroplasmy SNPs across the
entire mitochondrial genome.
NGS Sequencing
Primers were designed across the entire human mitochondrial
genome. A total of 171 primer pairs were designed that
overlapped each other to capture the intervening sequences.
A total of 100 ng of DNA per sample was used to construct
NGS libraries using the TruSeq Custom Amplicon kit (Illumina,
San Diego, CA). Two independent sets of primer pools were
synthesized. The two primer pools had primers that were
complementary. The two primer pools would interrogate the two
strands of the mitochondrial genome independently. The two
independent libraries had 48 samples each. NGS sequencing was
done using 96 libraries (for 48 samples X 2 pools) that were
loaded in 2 lanes for a 2 × 225 run on a HiSeq instrument
(Illumina). After sequencing, somatic variant analysis was carried
out using the variant caller—Pisces (21). Variant calls from each
pool were combined to get a list of “true” variants. True variants
are defined as variants present on both strands of the DNA.
The true variant list was used for final haplogroup analyses
using Haplogrep (http://haplogrep.uibk.ac.at). Variants present
on only one strand may represent DNA modification events or
other artifacts especially at low frequency and therefore were
eliminated from the final haplogroup analysis. This method
is capable of deep sequencing (average sequencing depth of
30,000; range 1,000–100,000) and accurately differentiates low
frequency mtDNA heteroplasmy SNPs from DNA modification
artifacts. The amino acid changes and association with diseases
resulting from some of the SNPs variants were verified using
www.MitoMap.org (22, 23). In some cases, the www.Phylotree.
org (24) was used to verify the positions of specific SNPs within
the Haplogroup H or Haplogroup J, and also determine if the
SNPs were elsewhere in the entire mtDNA tree Build 17. The rs
numbers were identified using www.ncbi.nlm.nih.gov/snp. The
website www.hmtvar.uniba.it, a database with over 40K human
mtDNA variants (25), was utilized to search for specific variants
using the Query Tab and inputting the SNP value into the
Position field to determine Mutation, Amino Acid Change (if
any), and Locus, as well as the link to external resources such as
dbSNP for rs numbers. All of the SNPs identified had a Quality
Score of 100 (A Phred-scaled quality score assigned by the variant
caller) and PASSed all of the Filters.
IC-50 Analysis of Cisplatin Titration Curve
Measuring Cell Viability
H and J cybrids were plated in 96-well plates (10,000 cells/well),
incubated for 24 h, and then treated with 0, 20, 40, 60, 80, 100,
or 120µM of cisplatin. The cybrids were incubated for another
48 h before having their cell viabilities measured with MTT
reagent (Cat. # 30006, Biotium, CA) and absorbance measured
with an ELx808 spectrophotometer (Biotek) at 570 nm with
reference wavelength at 630 nm. The background absorbance was
subtracted from the signal absorbance and values normalized
to the untreated specimen of each cell line. Each treatment was
analyzed with eight replicates. An IC-50 analysis was performed
to determine the concentration of cisplatin required to inhibit
the cell viability by 50% (GraphPad Prism Software, Inc., San
Diego, CA).
Cell Viability Assay
H and J cybrids were plated in six-well plates (500,000 cells/well)
and incubated for 24 h. Then cisplatin was added to media at
concentrations of 0, 25, or 50µM and incubated for another
48 h. Cells were counted using a Cell Viability Analyzer (ViCell,
Beckman Coulter, Miami, FL) that incorporates a Trypan blue
dye exclusion method. Cell numbers were normalized to H
untreated and analyzed using the two-tailed t-test (GraphPad
Prism). Experiments were analyzed in triplicate replicates and the
entire experiment was repeated twice.
Mitochondrial Membrane Potential
(19m) Assay
H and J cybrids were plated in 24-well plates (100,000 cells/well)
were incubated for 24 h and treated with 0 or 40µM of cisplatin
for another 48 h. JC-1 reagent (5,5′,6,6′-tetrachloro-1,1′,3,3′-
tetraethylbenzimidazolylcarbocyanine iodide) (Biotium,
Hayward, CA) was added to cultures for 15min. Fluorescence
wasmeasured using a Gemini XPSMicroplate Reader (Molecular
Devices) for red (excitation 550 nm and emission 600 nm) and
green (excitation 485 nm and emission 545mm) wavelengths.
Intact mitochondria with normal 19m appeared red, while
cells with decreased 19m were in a green fluorescent state.
Experiments were analyzed in quadruplicate and the entire
Frontiers in Oncology | www.frontiersin.org 5 July 2019 | Volume 9 | Article 640
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TABLE 1B | SNPs found by NGS in H Haplogroup Cybrids.
Loci: MT- SNP AA Change Locus rs# CY 10-03 CY 10-04 CY 10-07 CY 11-10 CY 11-23 CY 11-35 CY 13-49
CR:HV2 73 G>A NonCoding rs3087742 H H H H H H H
CR:HV2/
OHR
195 T>C NonCoding rs2857291 H4a1a+195
CR:HV3 456 C>T NonCoding rs41356551 H5’36
RNR1 750 A>G rRNA rs2853518 H2a H2a
RNR1 961 T>G rRNA rs3888511 H11a
RNR1 1198 A>G rRNA na PVT-b
RNR1 1438 A>G rRNA rs2001030 H H
RNR1 1477 T>C rRNA na PVT-b
tRNA Val 1630 A>C tRNA na H5
RNR2 1750 G>A rRNA rs28491689 PVT-b
RNR2 2159 T>C rRNA na H63
RNR2 2706 A>G rRNA rs2854128 H H H H H H H
RNR2 3010 G>A rRNA rs3928306 PVT-b PVT-a PVT-a
ND1 3926 T>C Leu207Pro na 14.22%
Htroplsmy
ND1 3992 C>T Thr229Met rs41402945 H4
ND1 4024 A>G Thr240Ala rs41504646 H4a
tRNA Gln 4336 T>C tRNA rs193303033 H5a
ND2 4483 C>G Ala5Gly na PVT-b
ND2 4733 T>C Syn:Asn88 na PVT-a
ND2 4769 A>G Syn:Met100 rs3021086 H2
ND2 4896 T>C Tyr143His na 4.39%
Htroplsmy
ND2 5004 T>C Syn:Leu179 rs41419549 H4a
ND2 5051 A>G Syn:Leu194 na H5a1i
ND2 5301 A>G Ile278Val rs199794187
NC3 5585 G>A NonCoding rs386828973 H11a2a2
CO1 6303 G>A Gly134Stop na 5.41%
Htroplsmy
CO1 6505 T>C Val201Ala rs28371932 12.21%
Htroplsmy
CO1 6951 G>A Val350Met na PVT-a
CO1 7028 T>C Syn:Ala375 rs2015062 H H H H H H H
CO1 7337 G>A Syn:Ser478 rs386829005 H66
CO2 8269 G>A Syn:Term228 rs8896 H4a1a
tRNA Lys 8343 A>G tRNA na PVT-a
ATP8 8448 T>C Met28Thr na H11
ATP8 8512 A>G Syn:Lys49 na
ATP6 9123 G>A Syn:Leu199 rs28358270 H4
(Continued)
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TABLE 1B | Continued
Loci: MT- SNP AA Change Locus rs# CY 10-03 CY 10-04 CY 10-07 CY 11-10 CY 11-23 CY 11-35 CY 13-49
CO3 9305 G>A Syn:Met33 na PVT-b
CO3 9771 T>C Ser189Pro na PVT-b
CO3 9777 G>A Gly191Ser na 13.99%
Htroplsmy
ND4L 10750 A>G Asn94Ser rs372297272 5.88%
Htroplsmy
ND4 11587 C>T Syn:Cys276 na PVT-b
ND4 11719 G>A Syn:Gly320 rs2853495 H H H H H H H
ND4 12130 T>C Syn:Phe457 na 9.53%
Htroplsmy
ND5 13759 G>A Ala475Thr rs386420019 H11
ND5 13889 G>A Cys518Tyr na H4a1a3
ND5 13911 A>G Syn:Met525 na PVT-b
ND5 14025 T>C Syn:Pro563 na PVT-a
ND6 14365 C>T Syn:Met73 rs2853815 H4a1
ND6 14582 A>G Val31Ala rs41354845 8.61%
Htroplsmy
ND6 14587 A>G Asp147Ala na H11a2
CYB 14861 G>A Ala39Thr rs2853505 4.96%
Htroplsmy
CYB 15670 T>C Syn:His308 rs527236211 H11a2a2
CYB 15833 C>T Syn:Leu363 rs41504845 H5a1
CR:TAS2 16092 T>C NonCoding na H11a2
CR:TAS2 16093 T>C NonCoding rs2853511 PVT-a
CR:7SDNA 16140 T>C NonCoding rs3134562 H11a2a
CR:7SDNA 16153 G>A NonCoding rs2853512 H5a1i
CR:7SDNA 16265 A>G NonCoding rs386829295 H11a2a2
CR:HV1 16293 A>G NonCoding rs386828867 H11a
CR:HV1 16304 T>C NonCoding rs386829305 H5
CR:HV1 16311 T>C NonCoding rs34799580 H11
PVT-a, found in other J or H haplogroups.
PVT-b, not found in other J or H haplogroups.
na, not available.
All SNP’s had a Quality (A Phred-scaled quality score assigned by the variant caller) Score of 100 and PASSed all the Filters.
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TABLE 1C | Diseases associated with SNPs* Identified in the J and H Cybrids.
Loci: MT- SNP AA Change Locus Cybrids with
SNP
Disease
RNR1 961 T>G rRNA H 1/7 Possible DEAF Associated
RNR2 3010 G>A rRNA J 7/7
H 3/7
Cyclic Vomiting Syndrome with Migraine
TER/TL1 3242 G>A tRNA J 1/7 Mitochondrial Myopathy/Maternally inherited Hypertrophic
Cardiomyopathy/ Renal Tubular Dysfunction; Myelodysplastic
syndrome
ND1 3394 T>C Tyr30His J 2/7 Leber Hereditary Optic Neuropathy/Carnitine PalmitoylTranserase
Deficiency/High Altitude Adaptation
ND1 4216 T>C Tyr304His J 7/7 Leber Hereditary Optic Neuropathy/Insulin Resistance/Possible
Adaptive High Altitude Variance
tRNA Q 4336 T>C tRNA H 1/7 Alzheimer’s Disease/Parkinson’s Disease/ Hearing Loss &
Migraine/Autism Spectrum/Intellectual Disability
ND2 5460 G>A Ala331Thr J 2/7 Alzheimer’s Disease/Parkinson’s Disease
tRNA C 5821 G>A tRNA J ‘1/7 Deaf Helper Mutation/Maternally inherited
DEAFness/Aminoglycoside-induced DEAFness
COI 6261 G>A Ala120Thr J 1/7 Prostate Cancer/Leber Hereditary Optic Neuropathy
tRNA K 8343 A>G tRNA H 1/7 Possible Parkinson’s Disease Risk Factor
ND3 10398 A>C Thr114Ala J 7/7 Parkinson’s Disease Protective Factor/Longevity/Altered Cell
pH/Metabolic Syndrome/Breast Cancer Risk/Attention Deficit
Hyperactivity Disorder/Cognitive Decline/SpinoCerebellar Ataxia
Type 2 Age Onset
ND5 13708 G>A Ala458Thr J 7/7 Leber Hereditary Optic Neuropathy/Increased Multiple Sclerosis
Risk/Higher Frequency in Parkinson’s Disease/Alzheimer’s Disease
ND6 14582 A>G Val31Ala H 1/7 Leber Hereditary Optic Neuropathy Synergistic 14258A + 14582G
CR:TAS2 16093 T>C NonCoding H 1/7 Cyclic Vomiting Syndrome
CR:HV1 16300 A>G NonCoding J 1/7 Bipolar Disorder Associated
*Information obtained from www.MitoMap.org and www.HmtVar.uniba.it.
experiment was repeated three separate times. Cisplatin-
treated values were compared to untreated values for statistical
significance (P ≤ 0.05, GraphPad Prism Software, Inc.).
Reactive Oxygen/Nitrogen Species
(ROS) Assay
H and J cybrids were plated in 24-well plates (100,000 cells/well)
and incubated for 24 h. Cells were treated with 0 or 40µM
of cisplatin for another 24 or 48 h. ROS levels were measured
with fluorescent dye 2,7-dichlorodihydrofluorescin diacetate
(H2DCFDA, Invitrogen-Molecular Probes, Carlsbad, CA) on a
fluorescence plate reader using 490 nm for emission and 520 nm
for excitation wavelengths (Gemini XPS Microplate Reader,
Molecular Devices, Sunnyvale, CA).
Our previous studies have shown that the J cybrids growmore
rapidly than H cybrids (17) so the ROS levels were normalized
per cell number. Simultaneously to the ROS experiments, H
and J cybrids were plated in 6 well-plates (500,000 cells/plate),
incubated 24 or 48 h, and treated in the identical fashion as
described above. Cell viabilities were assessed by the Beckman
Coulter ViCell Counter, allowing us to determine ROS levels per
cell numbers. Differences in cisplatin-treated cells compared to
untreated cells were analyzed (Prism, GraphPad Software Inc.)
and were considered to be statistically significant when P ≤ 0.05.
Experiments were analyzed in quadruplicate replicates and the
entire experiment repeated three separate times.
RNA Isolation, cDNA Synthesis, and
Quantitative Reverse Transcription
PCR (qRT-PCR)
H and J cells were plated (500,000 cells/well) and incubated for
24 h in six-well plates. Cells were treated with culture media
containing either 0 or 40µM of cisplatin for another 48 h.
Trypsinized cells were pelleted and RNA isolated following the
manufacturer’s protocol (RNeasy Kit, Qiagen, Valencia, CA).
After RNA quantification (Nanodrop 1000, Thermoscientific,
Wilmington, DE), the cDNA was transcribed from 100 ng
of RNA (Qiagen), and then used for quantitative reverse
transcription-PCR (qRT-PCR) (StepOnePlus instrument;
Applied Biosystems, Carlsbad, CA). SYBR Green-based primers
were used (Qiagen). Table 2A shows the GenBank Accession
numbers and functions for 23 genes that were investigated.
Cancer-related genes were Type 1 Cell-Surface Receptor for
TGF-beta ligand superfamily (ALK1), Cytochrome P450,
DNA Repair associated (BRCA1), Family 51, Subfamily A,
Polypeptide 1 (CYP51A), Dehydrogenase/Reductase Member 2
(DHRS2/HEP27), Epidermal Growth Factor Receptor (EGFR),
Erb-b2 Receptor Tyrosine Kinase 2 (ERBB2), Excision Repair
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FIGURE 1 | (A) Age and gender profiles for the J haplogroup (n = 7) and H haplogroup (n = 7) subjects. (B) Schematic derived from Haplogrep (https://haplogrep.
uibk.ac.at) showing the SNPs that define the J mtDNA haplogroups for subjects used in this study. (C) Schematic derived from Haplogrep (https://haplogrep.uibk.ac.
at) showing the SNPs that define the H mtDNA haplogroups for subjects used in the study. Red font, Haplogroup associated polymorphism missing. Green font,
Polymorphisms associated with haplogroup.
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TABLE 2A | Description of genes analyzed in cisplatin treated H and J cybrids.
Symbol Gene name Genbank
accession
numbers
Functions
CANCER-RELATED
ABCC1 ATP-Binding Cassette,
SubFamily C
NM_004996 Known as MRP1 (multidrug resistance protein 1). Member of the ATP binding
cassette family that transports molecules across membranes. Mutations in ABCC1
N-glycosylation connected with Cisplatin resistance.
ALK1 Type 1 Cell-Surface
Receptor for TGF-beta
ligand superfamily
NM_000020 Type Cell-Surface receptor for TGF-beta superfamily of ligands. Shares similar
domain structures in serine-threonine kinase subdomains with other activing
receptor-like kinase proteins.
BRCA1 DNA Repair associated NM_007294 Nuclear Phosphoprotein that acts as a tumor suppressor by maintaining genomic
stability. Involved in transcription, DNA repair of double-stranded breaks, and
recombination.
BMI1 Eukemia viral BMI-1
oncogene
NM_005180 Stem cell marker. Has key role in regulating the proliferative activity of both normal
and leukemic stem cells.
CDK2 Cyclin dependent kinase
2
NM_001798 Associated with apoptosis. Essential for completion of prophase I during meiotic
cell division in male and female germ cells.
CDKN1A/P21 Cyclin-dependent
kinase inhibitor 1A/ p21
NM_000389
NM_001220777
NM_001220778
NM_078467
NM_001291549
Plays a critical role in the cellular response to DNA damage and cisplatin toxicity.
Mediates cell cycle arrest. Is cyto-protective.
CYP51A Cytochrome P450,
Family 51, Subfamily A,
Polypeptide 1
NM_000786
NM_001146152
Member of the cytochrome P450 enzyme family of monooxygenases.
DHRS2/
HEP27
Dehydrogenase/
Reductase (SDR Family)
Member 2
NM_182908
NM_005794
NADPH-dependent dicarbonyl reductase activity. Mitochondrial matrix protein.
Inhibits MDM2 and stabilizes p53.
EGFR Epidermal Growth
Factor Receptor
NM_005228 Triggers cell proliferation when bound to epidermal growth factor
ERBB2 Erb-b2 Receptor
Tyrosine Kinase 2
NM_004448 Member of epidermal growth factor receptor family of receptor tyrosine kinases.
Stabilizes binding of epidermal growth factor to receptor
ERCC1 Excision Repair
Cross-Complementation
Group 1
NM_001166049
NM_001983
NM_202001
Nucleotide Excision Repair formed by electrophilic compounds such as Cisplatin.
Forms a heterodimer with XPF endonuclease. Involved in recombination DNA
repair, inter-stand crosslink, and lesion repair.
KAT5/
TIP60
K (Lysine)
acetyltransferase 5
NM_001206833
NM_006388
NM_182709
NM_182710
Drug resistance; has role in acetylation of histones; modulates DNA damage
response.
SFRP1 Secreted frizzled-related
protein 1
NM_003012 Soluble modulators of Wnt signaling. Regulates cell growth and differentiation.
Silencing leads to deregulated pathway, associated with cancer.
TP53 Tumor protein p53 NM_000546
NM_001126112
NM_001126113
NM_001126114
NM_001126115
NM_001126116
NM_001126117
NM_001126118
NM_001276695
NM_001276696
NM_001276697
NM_001276698
NM_001276699
NM_001276760
NM_001276761
Regulates genes that induce cell cycle arrest, apoptosis, senescence, DNA repair,
or changes in metabolism. Induces apoptosis.
(Continued)
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TABLE 2A | Continued
Symbol Gene name Genbank
accession
numbers
Functions
APOPTOSIS
BAX BCL2-Associated X
Protein
NM_001291429
NM_001291428
NM_001291430
NM_138761
NM_004324
NM_138764
NM_001291431
NM_138763
Associates to form a heterodimer with BCL2. Functions in apoptotic behavior by
opening the mitochondrial voltage dependent anion channel, leading to loss of
membrane potential, and opening of cytochrome C.
BBC3 BCL2 Binding
Component 3
NM_001127240
NM_001127241
NM_014417
Member of the BCL-2 family. Induces mitochondrial membrane permeablization
and apoptosis.
BCL2L13 BCL2-Like-1 NM_015367
NM_001270729
NM_001270731
NM_001270732
NM_001270734
NM_001270735
BCL2 isoform. Mitochondrial-localized protein. Overexpression results in
apoptosis.
CASP3 Caspase-3 NM_004346
NM_032991
Effector caspase; Activated by caspases 8, 9, and 10. Effects caspases 6, 7, 9.
Belongs to family of proteases involved in apoptosis; Synthesized as inactive
precursors and therefore need activation.
CASP9 Caspase-9 NM_001229
NM_032996
Part of the apoptosome protein complex formed during apoptosis. Mitochondrial
caspase activation.
SIGNALING
EFEMP1 EGF-Containing
Fibulin-Like Extracellular
Matrix Protein-1
NM_001039349
NM_001039348
Fibulin family of extracellular matrix glycoproteins. Binds to epidermal growth factor
receptors causing phosphorylation and signaling.
Associated with drug resistance and cancer prognosis.
FOXM1 Forkhead Box M1 NM_001243088
NM_001243089
NM_021953
NM_202002
NM_202003
Transcriptional activator involved in cell proliferation.
Regulates expression of several cyclins.
Role in DNA break repairs.
Phosphorylated and inactivated during mitosis.
MAPK8 Mitogen-activated
protein kinase 8
NM_002750
NM_139046
NM_139047
NM_139049
NM_001278547
NM_001278548
Targets specific transcription factors. Mediates immediate-early gene expression.
Involved in UV radiation induced apoptosis.
MAPK10 Mitogen-activated
protein kinase 10
NM_002753
NM_138980
NM_138982
Regulatory role in signaling pathways during neuronal apoptosis;
Inhibited by cyclin dependent kinase 5.
HOUSEKEEPERS
ALASV1 5’-amino-levulinate
synthase 1
NM_000688 Mitochondrial enzyme catalyzes rate-limiting step in heme biosynthesis. Level of
the mature encoded protein regulated by heme.
GUSB Glucuronidase, beta NM_000181
NM_001284290
NM_001293104
NM_001293105
Belongs to the glycosidase family of enzymes that break down complex
carbohydrates.
HMBS Hydroxy-methylbilane
synthase
NM_000190
NM_001024382
NM_001258208
NM_001258209
Third enzyme of heme biosynthetic pathway; Catalyzes condensation of four
porphobilinogen molecules into hydroxymethylbilane.
HPRT1 Hypoxanthine
phosphor-ribosyl-
transferase
1
NM_000194 Transferase catalyzes conversion of hypoxanthine to inosine monophosphate and
guanine to guanosine monophosphate.
TUBB Tubulin beta
class I
NM_178014
NM_001293213
Part of protein superfamily of globular proteins. Major component of microtubules.
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TABLE 2B | Expression levels in cisplatin treated H and J cybrids.
Symbol Untreated
Cybrids
H# vs. J
P value, Fold
H Cybrids
Untreated# vs
Treated
P value, Fold
J Cybrids
Untreated# vs.
Treated
P value, Fold
Treated
Cybrids
H# vs. J
P value, Fold
CANCER-RELATED GENES
ABCC1 0.35,
0.77 ± 0.19
0.24,
0.82 ± 0.078
0.21,
0.63 ± 0.095
0.02,
0.56 ± 0.084
CDKN1A/P21 0.61,
1.41 ± 0.66
0.002,
4.89 ± 0.51
0.12,
3.12 ± 0.65
0.13 0.68
± 0.14
CYP51A 0.63,
1.14 ± 0.14
0.12,
2.01 ± 0.47
0.0057,
1.94 ± 0.12
0.75,
1.14 ± 0.07
DHRS2/HEP27 0.47,
0.79 ± 0.17
0.89,
1.08 ± 0.14
0.75,
1.12 ± 0.42
0.02,
0.53 ± 0.06
APOPTOSIS GENES
BAX 0.97,
1.01 ± 0.09
0.32,
1.32 ± 0.26
0.05,
1.78 ± 0.26
0.28,
1.4 ± 0.21
CASP3 0.63,
1.14 ± 0.14
0.12,
2.01 ± 0.47
0.02,
3.33 ± 0.62
0.57,
1.4 ±0.26
SIGNALING GENES
EFEMP1 0.57,
0.79 ± 0.32
0.14,
0.69 ± 0.16
0.34,
0.43 ± 0.21
0.04,
0.31 ± 0.08
SFRP1 0.49,
0.97 ± 0.30
0.28,
0.53 ± 0.26
0.05,
0.14 ± 0.04
0.19,
0.77 ± 0.21
Fold values >1 indicate up-regulation of the gene.
Fold values <1 indicate down-regulation of the gene.
# are assigned a value of 1.
P values ≤ 0.05 are statistically significant and are bolded.
Cross-Complementation Group 1 (ERCC1), and Secreted
frizzled-related protein 1 (SFRP1). We also examined genes
involved in cisplatin-induced nephrotoxicity and resistance
(26, 27): ATP-Binding Cassette, Sub-Family C (ABCC1),
Eukemia viral BMI-1 oncogene (BMI1), Cyclin-dependent
kinase 2 (CDK2), Cyclin-dependent kinase inhibitor 1A
(CDKN1A/P21), Lysine acetyltransferase 5 (KAT5/TIP60), and
Tumor protein p53 (TP53).
Apoptosis genes were BCL2-associated X protein (BAX),
BCL2 Binding Component 3 (BBC3), BCL2-Like-13 (BCL2L13),
Caspase-3 (CASP3), and Caspase-9 (CASP9). Signaling genes
include EGF-Containing Fibulin-Like Extracellular Matrix
Protein-1 (EFEMP1), Mitogen-activated protein kinase 8
(MAPK8), Mitogen-activated protein kinase 10 (MAPK10), and
Forkhead Box M1 (FOXM1). Target cycle thresholds (Ct) values
were initially compared to the Ct values of reference genes and
subsequently, comparisons between untreated and cisplatin-
treated values (11Ct) were evaluated for statistical significance.
Fold differences were calculated using the equation 2(11Ct).
Statistical Analyses
Statistical analysis of the data was performed by ANOVA
(GraphPad Prism, version 5.0). Newman-Keuls multiple-
comparison or the two-tailed t-tests were used to compare
the data within each experiment. P ≤ 0.05 was considered
statistically significant. Error bars in the graphs represent
standard error of the mean (SEM).
RESULTS
Sequencing of mtDNA From H and
J Cybrids
The entire mtDNA from the J and H cybrids were sequenced
using NGS technology. Figure 1A shows the age and gender
of person in this study. The private SNPs are those that do
not define the J or H haplogroups (non-haplogroup defining).
The unique SNPs are not listed in www.MitoMap.org or other
programs. Table 1A shows the SNPs in the J haplogroup
cybrids. There were 11 private SNPS in the mtDNA regions
of the J cybrids: CYB 10-01 with m.2305T>C (unique, no
rs#, MT-RNR2, unique) and m.10654C>T (no rs#, MT-ND4L,
Ala62Val); CYB 10-05 withm.7226G>A (rs369835151,MT-CO1,
Syn:Ser441); m.13143 (rs386829174, MT-ND5, Syn:Asn269); and
with m.16209T>C (rs386829278, MT-CR, NonCoding); CYB
11-32 with m.6734G>A (rs41413745, MT-CO1, Syn:Met332);
CYB 13-43 with m.3847T>C (no rs#, MT-ND1, Syn:Leu181);
m7805G>A (no rs#, MT-CO2, Val74Ile) and m.14208A>G
(no rs#, MT-ND6, Thr156Ala); m.16263T>A (rs386829294,
CR;HV1, NonCoding); CYB 13-62 with m.6899GA (no rs#,
MT-CO1, Syn:Met332); and CYB 13-107 with m.8200T>C (no
rs#, MT-CO2, Syn:Ser205) (Table 1A). The non-coding Control
Region (CR) of the J cybrids possessed 17 SNPs and 10 of
those defined the J haplogroup. The NGS methodology allowed
identification of heteroplasmic SNPs in the J cybrids. The
13 heteroplasmy SNPs showed a range from 3.1 to 17.29%
occurrence in five of the seven cybrids. CYB 10-05 andCYB 13-74
lacked heteroplasmy in the mtDNA.
Table 1B shows the SNPs in the H haplogroup cybrids. There
were 12 private SNPS in the mtDNA regions of the H cybrids:
CYB 10-03 with m.1198A>G (no rs#, MT-RNR1), m.1477T>C,
(no rs#, MT-RNR1) m.4483C>G (unique, no rs#, MT-ND2),
m.9305G>A, (no rs%, MT-CO3, Syn:Met33), m.9771T>C,
(unique, no rs#, MT-CO3, Ser189Pro); m.16093T>C (rs2853511,
CR:TAS2, NonCoding); CYB 11-23, with m.1750G>A,
(rs28491689, MT-RNR2); m.3010G>A (rs3928306, MT-
RNR2); m.11587C>T, (no rs#, MT-ND4, Syn:Cys276); CYB
11-35 with m.3010G>A, (rs3928306, MT-RNR2); and CYB
13-49 with m.13911A>G, (no rs#, MT-ND5, Syn:Met525); and
m.14025T>C (no rs#, MT-ND5, Syn:Pro563). There were 8
SNPs in the non-coding Control Region with seven of those
defining the H haplogroup. Four of the cybrids (CYB 10-07, CYB
11-10, CYB 11-23, and CYB 13-49) possessed heteroplasmy that
ranged from 4.39 to 14.22%. The SNP variants associated with
human diseases are listed in Table 1C. The m.3010G>A variant
(found in all seven of the J haplogroup cybrids and three of the H
haplogroup cybrids) is associated with cyclic vomiting syndrome
and migraines. The other SNP variants listed are found in either
the J cybrids or the H cybrids but not both.
IC50 Analyses Results
IC-50 analyses were performed to determine the concentration of
cisplatin required to inhibit the cell viability by 50% (Figure 2).
The Goodness of Fit values were R2 = 0.8388 and R2 = 0.8828
for the H and J cybrids, respectively. The IC-50 values for cybrid-
H were 47.13µM (95% confidence interval 38.62–57.53µM) and
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FIGURE 2 | The IC-50 values for the J cybrids were lower (41.06µM) compared to the H cybrids (47.13µM). H and J cybrids were plated in 96-well plates, treated
with 0, 20, 40, 60, 80, 100, or 120µM of cisplatin and the cell viabilities measured with MTT reagent. The Goodness of Fit values for the H cybrids were R2 = 0.8388
and 95% confidence interval 38.62–57.53µM. The J cybrid Goodness of Fit values were R2 = 0.8828 and 95% confidence interval 29.49–57.18µM. Each treatment
was analyzed with eight replicates.
for cybrid-J were 41.06µM (95% confidence interval 29.49 and
57.18 µM).
Viability of H and J Cybrids After
Cisplatin Treatment
The H and J cybrids were treated for 48 h with either 0, 25, or
50µM cisplatin and cell viabilities measured using a Trypan Blue
dye exclusion assay. The cell viability for the untreated J cybrid
(Cyb J Unt) was normalized to the untreated H cybrids (Cyb
H Unt, 100.0% ± 16.3). Without treatment, the J cybrids grew
at a faster rate than H cybrids (226.5% ± 30.7 vs. 100.0% ±
16.3, P = 0.001, Figure 3A). Cell viability of H cybrids decreased
13% (P = 0.58) after 25µM cisplatin treatment and to 38% (P
= 0.05) after 50µM cisplatin treatment compared to untreated-
H cybrids (100.0% ± 16.3). Compared to untreated-J cybrids,
viability decreased 35% (P = 0.04) and 65% (P = 0.002) for the
25 and 50µM cisplatin-treated-J cybrids, respectively. Thus, cell
viabilities of J cybrids were more sensitive to cisplatin treatment
than those of H cybrids.
Mitochondrial Membrane Potential (19m)
After Cisplatin Treatment
The effects of cisplatin on the 19m of H and J cybrids were
analyzed after 48 h incubation (Figure 3B). The cisplatin-treated-
H cybrids showed similar 19m compared to the untreated-H
cybrids (105.3% ± 7.45 vs. 100.0% ± 2.6, P = 0.51, respectively).
The cisplatin-treated-J cybrids showed a significant reduction
of 19m compared to the untreated-J cybrids (75.9% ± 3.6 vs.
100.0% ± 2.0, P = 0.0001, respectively). In addition, cisplatin-
treated-J cybrids showed a 29.4% decrease in Relative Fluorescent
Units (RFU) compared to cisplatin-treated-H cybrids (75.9% ±
3.6 vs. 105.3% ± 7.5, P = 0.0005). These findings indicate that J
cybrids have a greater loss of19m after cisplatin treatment than
H cybrids.
Reactive Oxygen Species (ROS)
Production After Cisplatin Treatment
The ROS levels, measured in RFU, were compared between the
H and J cybrids with and without cisplatin treatments after 48 h
incubation (Figure 3C). The cisplatin-treated-J cybrids showed
significantly lower ROS compared to the untreated-J cybrids
(56.79% ± 7.731 vs. 78.33% ± 4.24, P = 0.03, respectively) and
also compared to cisplatin-treated-H cybrids (98.26% ± 8.66, P
= 0.03). There was no difference between the cisplatin-treated-
H cybrids and untreated-H cybrids after 48 h incubation (P
= 0.37). Since ROS production levels had been normalized to
cell viability for each condition, our findings showed that after
cisplatin treatment, the J cybrid cultures showed significantly less
ROS production compared to H treated cybrid cultures.
Gene Expression Levels in H and J Cybrids
Treated With Cisplatin
Cancer-Related Pathway Genes
The CYP51A gene expression levels were similar in untreated-H
and untreated-J cybrids (1.14 ± 0.14-fold, P = 0.63, Table 2B).
However, after cisplatin treatment, the J-treated cybrids showed
increased transcription levels compared to untreated-J cybrids
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FIGURE 3 | (A) The J cybrids were more sensitive to cisplatin treatment than
the H cybrid cultures. Cell viabilities of the untreated and cisplatin-treated
cybrids were measured using the trypan blue dye exclusion assay and
normalized to the untreated-H cybrid sample (Cyb H Unt, 100.0 ± 16.3). The
viability in untreated-J cybrids increased at 2.26-fold higher rate than the
(Continued)
FIGURE 3 | untreated-H cybrids (P = 0.001). The viability declined in the
25µM cisplatin-treated-H cybrids (13%, P = 0.58) and 50µM
cisplatin-treated-H cybrids (38%, P = 0.05) compared to the untreated-H
cybrids. The viability decreased in the 25µM cisplatin-treated-J cybrids (35%,
P = 0.05) and 50µM cisplatin-treated-J cybrids (65%, P = 0.002) compared
to the untreated-J cybrids. Each experiment was repeated twice and analyzed
in triplicate. (B) J cybrids have a greater loss of mitochondrial membrane
potential (1Ψm) after cisplatin treatment than H cybrids. The 1Ψm values in
cisplatin-treated-J cybrids were significantly decreased compared to the
untreated-J cybrids (P = 0.0001) and also the cisplatin-treated H cybrids (P =
0.0005). In contrast, the cisplatin-treated and untreated-H cybrids showed
similar levels to each other (P = 0.51). 1Ψm, mitochondria membrane
potential; RFU, relative fluorescent units. *P < 0.05; **P < 0.01; ***P < 0.001.
(C) Cisplatin-treated-H cybrids produced higher levels of ROS compared to
the cisplatin-treated-J cybrids. The ROS levels, as measured in relative
percentile, were compared between the H and J cybrids without and with
cisplatin treatments after 48 h. The cisplatin-treated-J cybrids had significantly
lower ROS levels compared to the untreated-J cybrids (P = 0.03) and also
compared to the cisplatin-treated-H cybrids (P = 0.006). The ROS levels for
the untreated H and cisplatin-treated H were similar to each other (P = 0.37).
RFU = relative fluorescent units. *P < 0.05.
(1.94 ± 0.12-fold, P = 0.0057) while the cisplatin-treated-H
cybrids were similar to untreated-H cybrids (P = 0.12).
Levels of CDKN1A/p21 were similar in untreated-J and H
cybrids (P = 0.61) but the cisplatin-treated-H cybrids showed
significant upregulation compared to the untreated-H cybrid
(4.89 ± 0.51-fold, P = 0.002; Table 2B). The CDKN1A/p21
levels in cisplatin-treated-J cybrids trended higher, but were
not significant (3.12-fold, P = 0.12). Gene expression levels of
both ABCC1 and DHRS2/HEP27 in cisplatin-treated-J cybrids
were significantly lower than that of cisplatin-treated-H cybrids
(0.56 ± 0.084-fold, P = 0.02 and 0.53 ± 0.06-fold, P =
0.02, respectively). The cisplatin-treated-J cybrids had decreased
SFRP1 gene expression levels compared to untreated-J cybrids
(0.14 ± 0.04-fold, P = 0.05). In contrast, the untreated-
H and cisplatin-treated-H cybrids were SFRP1 levels were
similar to each other (P = 0.28). These findings demonstrate
that expression levels of ABCC1, CYP51A, CDKN1A/p21,
DHRS2/HEP27, and SFRP1 genes are differentially influenced in
cells containing H vs. J mtDNA profiles.
The levels of ALK, BRCA1, BMI1, CDK2, EGFR, ERBB2,
ERCC1, KAT5/TIP60, and TP53 were not different from each
other in the H and J cybrids under any conditions (with or
without cisplatin treatment; data not shown).
Apoptosis Pathway Genes
Untreated-H and untreated-J cybrids expressed similar levels of
BAX (1.01-fold, P = 0.97). After cisplatin exposure, BAX, and
CASP3 levels increased in cisplatin-treated-J cybrids compared
to the untreated-J cybrids (1.78 ± 0.26-fold, P = 0.05 and 3.33
± 0.62-fold, P = 0.02, respectively). In contrast, the treated
and untreated-H cybrids were not significantly different from
each other (BAX, P = 0.32 and CASP3, P = 0.12). The BBC3,
BCL2L13, and CASP9 gene levels were similar in H and J cybrids
with or without cisplatin treatment, indicating that cisplatin did
not affect these apoptotic genes. These findings indicate that in
the J cybrids, cisplatin-induced apoptosis upregulation of BAX
and CASP3.
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Signaling Pathway Genes
The cisplatin-treated-J cybrids demonstrated lower EFEMP1
gene expression levels than cisplatin-treated-H cybrids (0.31
± 0.08-fold, P = 0.04). The MAPK8, MAPK10, and FOXM1
expression levels were not different between H and J cybrids, nor
were they affected by cisplatin treatment (data not shown).
Target Sites for Cisplatin Within the
MT-Dloop and Comparison of mtDNA
GG Stretches
The entire control regions of H (n = 6) and J (n = 7) cybrids
were sequenced (Table 3) and analyzed for the numbers of GG
stretches, which are known to be target DNA sequences for
cisplatin (28). The MT-Dloop was analyzed because it is the
region controlling replication and transcription for mtDNA. In
H cybrids (n = 6) and J cybrids (n = 7) there were three
GGG stretches (nt16455-16457; nt16516-16518, and nt34-36),
oneGGGGG stretch (nt16470-16474), and oneGGGGGG stretch
(nt66-71) site. One H cybrid had a GGGG stretch (nt322-325)
that was lacking in any of other H or J cybrids. Greatest variability
was found in regions of GG stretches: nucleotides (nt) 184-
185 (5/7 in J cybrids); nt228-229 (4/7 in J cybrids); nt322-323
(5/6 in H cybrids); nt513-514 (1/6H cybrids); and nt526-527
(1/6H cybrids). A difference in GG stretch patterns of H vs. J
cybridsmay potentially lead to variations in numbers of cisplatin-
mtDNA adducts. However, we believe additional studies will be
needed to clarify mechanisms of interaction between the mtDNA
and cisplatin that might affect cellular responses.
DISCUSSION
Cell Culture Studies
Although cybrids have identical nuclei and culture conditions,
the cell lines with J haplogroup mtDNA exhibit different
responses to cisplatin than cybrids with H haplogroup mtDNA.
The untreated-J cybrids have significantly increased rates of
growth compared to untreated-H cybrids (226 vs. 100%, P
= 0.001), a finding consistent with a previous study (17).
After treatment with cisplatin, J cybrids show a dose-dependent
decrease in cell viability with a 35% decline at 25µM cisplatin
(P = 0.044) and 58% decline at 50µM cisplatin (P = 0.0023)
compared to the untreated-J cultures. In contrast, H cybrids had
non-significant 12% decrease at 25µMand 38% decline at 50µM
(P = 0.05) compared to the untreated-H cybrids. The large
decline in cell viability for J cybrids may be because cisplatin,
similar to many anti-cancer drugs, is more effective on rapidly
growing cells (1), which is the status of cells containing J mtDNA
haplogroup patterns (17, 29). Alternatively, it may be that the
differential effects of cisplatin are related to J cybrids having lower
oxygen consumption, ATP levels, and mitochondrial membrane
potential (17, 30). Interestingly, Ghelli et al. reported that
Leber’s Hereditary Optic Neuropathy (LHON) cell lines with the
J haplogroup showed increased sensitivity to 2,5-hexanedione
(2,5-HD), a toxic solvent that causes neurological and retinal
pathology after exposure (31).
The 19m decreased significantly in cisplatin-treated-J
cybrids but not in cisplatin-treated-H cybrids compared to their
untreated controls. The decline in19m represents early changes
that can lead to downstream events such as apoptosis. The
release of cytochrome C and induction of intracellular apoptosis
are mediated through the voltage-dependent anion channel
(VDAC) and cisplatin binds to cysteine and methionine sites
of the VDAC (32). The mitochondrial size, shape, and degree
of fragmentation can affect binding capacity of BAX, causing
changes in mitochondrial outer membrane permeability and
apoptosis. The lower 19m levels in cisplatin-treated-J cybrids
are consistent with qRT-PCR results showing increased apoptotic
gene expressions (BAX and CASP3) compared to untreated-J
cybrids, while the levels in H cybrids did not vary after cisplatin
treatment. Our findings show that the mtDNA variants within
cells can mediate cisplatin-induced pro-apoptosis events that
might contribute to the degrees of toxicity and/or resistance in
different individuals.
The cisplatin-treated-H cybrids showed higher ROS levels
compared to the cisplatin-treated-J cybrids, which is not
completely surprising because the H cybrids utilize OXPHOS,
a system that can generate endogenous ROS, while J cybrids
use predominantly glycolysis (17). In addition, there are reports
that cisplatin reduces mitochondrial respiration complexes I-
IV activity by 15–55%, resulting in higher ROS generation in
porcine proximal tubular cells (33). A similar stimulus of ROS
production may occur in H cybrids because of their reliance on
the OXPHOS bioenergetics.
The RPE cell line used in this study is non-cancerous
(ARPE-19) and cancer cells genomes may respond differently
to cisplatin treatment. One side effect of cisplatin therapy is
mild to moderate pigmentary retinopathy (abnormalities of the
RPE cells) that occurs in some patients but not in others. Our
findings demonstrate that in vitro the human RPE cells are
affected deleteriously by cisplatin treatment but depending upon
the mtDNA haplogroup (H vs. J), the responses are differentially
expressed. This differential response may contribute to the
pigmentary retinopathy found in some patients but lacking in
other subjects (7).
Gene Expression Studies
Differentially Expressed Genes
We looked at several genes involved with apoptosis: BAX,
BBC3, BCL2L13, CASP9, and CASP3. RNA levels for BAX and
CASP3 were upregulated in cisplatin-treated-J cybrids compared
to untreated-J cybrids, but the H treated cybrids remained
similar to untreated controls. Cisplatin-induced upregulation of
CASP3, the downstream effector gene for apoptosis, has also
been reported in carcinoma cells (34). Consistent with elevated
apoptosis genes, RNA levels for BAX were upregulated after
cisplatin treatment in J cybrids in comparison to untreated-
J cybrids. BAX proteins help form porous defects in the
mitochondrial outer membrane, leading to release of apoptotic
factors (26). In a mouse model, cisplatin has been shown to
induce BAX in renal tubular cells (35). Mice deficient of BAX
show less cytochrome C release from mitochondria, lower levels
of renal tubular apoptosis, and increased resistance to cisplatin
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TABLE 3 | Total numbers of GG stretches in the MT-Dloop (nt16441 to nt601) of H cybrids vs. J cybrids.
mtDNA
Haplogroup
Total
nucleotides
GG GGG GGGG GGGGG GGGGGG
H 760 nt16503-16504 (6/6)
nt16569-01 (6/6)
nt08-09 (6/6)
nt53-54 (6/6)
nt100-101 (6/6)
nt106-107 (6/6)
nt184-185 (6/6)
nt228-229 (6/6)
nt322-323 (5/6)
nt409-410 (6/6)
nt412-413 (6/6)
nt513-514 (1/6)
nt526-527 (1/6)
nt16455-16457 (6/6)
nt16516-16518 (6/6)
nt34–36 (6/6)
nt322-325 (1/6) nt16470-16474 (6/6) nt66-71 (6/6)
J 760 nt16503-16504 (7/7)
nt16569-01 (7/7)
nt08-09 (7/7)
nt53-54 (7/7)
nt100-101 (7/7)
nt106-107 (7/7)
nt184-185 (5/7)
nt228-229 (4/7)
nt322-323 (7/7)
nt409-410 (7/7)
nt412-413 (7/7)
nt16455-16457 (7/7)
nt16516-16518 (7/7)
nt34–36 (7/7)
0 nt16470-nt16474
(7/7)
nt66-71 (6/6)
H, n = 6; J, n = 7.
(35). Further studies into the mechanisms of BAX and CASP3
upregulation in our cybrids are needed.
SFRP1 levels were not significantly changed after cisplatin
treatment in H cybrids. In contrast, the SFRP1 levels were lower
in cisplatin-treated-J cybrids compared to untreated-J cybrids
(P = 0.05). This is significant because all nuclei and culture
conditions are identical, indicating that cisplatin has different
effects on cells depending on whether they contain H or J
mtDNA. SFRP1 is an extracellular inhibitor of theWNT pathway
and acts as a tumor suppressor. Lower SFRP1 levels, as seen in
the cisplatin-treated-J cybrids, can be associated with resistance
to cisplatin and poorer patient survivability (36).
The CDKN1/p21 gene levels were higher after cisplatin
treatment in H cybrids compared to untreated-H cybrids (P
= 0.002). In contrast, the CDKN1/p21 gene levels were not
changed in the J cybrids after treatment (P = 0.12). Higher
levels of CDKN1/p21 are significant because of its role in cellular
responses to DNA damage and cell cycle arrest. Overexpression
of p21 inhibits colony formation of tumor cells (37). In addition,
Duensing et al. reported that abnormal expression of p21 is
associated with chromosomal instability as seen in tumor cells
(38). Usually, induction ofCDKN1AmRNA level is dependent on
Tp53 (39) but in our H and J cybrids, the Tp53 expression levels
were not changed in response to cisplatin treatment (data not
shown). This suggests that upregulation of CDKN1A/p21, as seen
in cisplatin-treated-H cybrids, is independent ofTp53 expression.
There was an interesting disparity in the J and H cybrids after
cisplatin treatment. The untreated-H and J cybrids had similar
expression levels for ABCC1, DHRS2/HEP27, and EFEMP1 but
after cisplatin-treatment, the treated-J cybrids showed lower
expression levels compared to the untreated-J cybrids (P = 0.02,
P = 0.02, and P = 0.04, respectively), while the cisplatin-treated-
H were similar to the H-untreated. After cisplatin treatment,
higher expression levels of DHRS2/HEP27 were found in the
cisplatin-treated-H cybrids compared to the cisplatin-treated-
J cybrids. An accumulation of DHRS2/HEP27 pre-protein in
the mitochondria matrix can lead to mature DHRS2/HEP27
translocating to the nucleus, where it eventually binds and
inhibits MDM2, leading to stabilization of the Tp53 pathway
and indirect tumor repressor functions within the cell. Higher
levels of DHRS2/HEP27 gene expression in cisplatin-treated-H
cybrids could be associated with MDM2-mediated breakdown
of the Tp53 gene, and ultimately stabilization of cellular
homeostasis (40).
ABCC1 functions as a transporter, mediates export of drugs
from the cytoplasm, and also confers resistance to anti-cancer
drugs (41, 42). In osteosarcoma cells, ABCC1 was the most
relevant transporter associated with drug resistance, along with
the ABCB1 transporter (27). After cisplatin treatment, up-
regulations of ABCC1 and EFEMP1 were found in the cisplatin-
treated-H cybrids compared to the cisplatin-treated-J cybrids.
The higher ABCC1 levels in H cybrids suggest these cells may
be more likely to become resistant to anticancer drugs than cells
with J mtDNA. If our in vitro findings represent in vivo events,
then patients with J haplogroup mtDNA might be less likely to
become resistant to anticancer drugs while the H haplogroup
patients are more likely. EFEMP1 is a gene associated with the
production of EGF-containing fibulin-like extracellular matrix
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protein 1. Overexpression of this gene has been linked to in
vivo and in vitro chemotherapeutic drug resistance in cases
used to treat glioblastoma tumor growth. The higher EFEMP1
gene expression levels in H cybrids may be a precursor to drug
resistant cybrid cells treated with cisplatin (43). Future studies
should be conducted to determine if there is correlation between
mtDNA haplogroup patterns and cisplatin resistance.
Based upon our findings, it is apparent that after cisplatin
treatment, cells containing J haplogroups (Northern European)
variants show different biological behavior and gene expression
patterns compared to those cells possessing the Southern
European H haplogroup mtDNA. At this time, it is not clear
how the H vs. J mtDNA profiles influence the nuclear gene
expression in cybrids. The effects may be not strictly related to the
haplogroup mtDNA as a whole but rather the presence of specific
SNPs, which in this case, are defining the J haplogroup. For
example, them10398A>Gpolymorphism (MT-ND3, ALA-THR)
defines the J haplogroup (www.MitoMap.org). The m10398A>G
has been associated with breast cancer in African-American
women (44), although no association was found in another
study (45). Another J haplogroup-defining SNP, m13708G>A
(MT-ND5, ALA-THR), has also been associated with breast
cancer (46). Even though these SNPs were located in different
mtDNA encoding genes, each of these has an amino acid change
from Alanine, a non-polar, neutral amino acid to the polar,
neutral Threonine, which could change bonding and function
of proteins. In contrast, when mtDNA from H cybrids were
sequenced, there were no mtDNA variant/mutations that have
been associated with human cancers (47). One can speculate that
one or all of these J haplogroup-defining SNPs can contribute to
changes in retrograde signaling between the mtDNA and nuclear
genomes. While further work is needed to identify mechanisms
and pathways, our findings support the hypothesis that an
individual’s mtDNA background can contribute to the response
to cisplatin, which is important for the drug’s efficacy, level of side
effect and development of resistance.
In summary of the gene expression studies, the effects
of cisplatin on gene expression fell into five categories
(Figure 4). The first category was that cisplatin did not
change gene expression in either cisplatin-treated-J or
FIGURE 4 | Schematic showing the changes in gene expression levels for H and J cybrids after cisplatin treatment fall into different categories: (1) there are no
differences in the expression levels between the untreated and cisplatin-treated cybrids (MAPK8, MAPK10, FOXM1, BBC3, BCL2L13, CASP9, ALK1, BRCA1, EGFR,
ERBB2, ERCC1, CDK2, TP53, BMI1, and KAT5/TIP60). (2) Lower expression levels of SFRP1 are found in the cisplatin-treated-J cybrid compared to the untreated-J
cybrid; (3) Upregulation of CYP51A, BAX, and CASP3 in the cisplatin-treated-J cybrids compared to the untreated-J cybrids; (4) Higher levels of CDKN1A/P21 are
found in the cisplatin-treated H cybrids compared to the untreated H cybrids; (5) The H-cisplatin cybrids showed higher expression levels of DHRS2/HEP2, ABCC1,
and EFEMP1 compared to the cisplatin-treated-J cybrids.
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cisplatin-treated-H cybrids (MAPK8, MAPK10, FOXM1,
BBC3, BCL2L13, CASP9, ALK1, BRCA1, EGFR, ERBB2,
ERCC1, CDK2, TP53, BMI1, and KAT5/TIP60). The second
category was that cisplatin-treated-J cybrids were downregulated
(SFRP1) and the third category showed upregulation (CYP51A,
BAX, or CASP3) compared to the untreated-J cybrids. The
fourth category was that cisplatin-treated-H cybrids showed
increased transcription of CDKN1A/p21 gene compared to
untreated-H cybrids, while the J cybrid levels were not affected.
Finally, that cisplatin-treated-J cybrids showed lower levels
of gene expression compared to cisplatin-treated-H cybrids
(DHRS2/HEP27, ABCC1, and EFEMP1).
Sequencing of the Entire mtDNA
NGS analyses performed on the mtDNA from each of the H
and J cybrids showed that the majority of the SNPs identified
were haplogroup defining. The private SNPs (non-haplogroup
defining), unique SNPs (not listed in www.MitoMap.org), and
heteroplasmy SNPs were found in individual cybrids and not
throughout all of the H or J cybrids. This suggests that the
differential retrograde signaling between the H and J mtDNA
haplogroups is due to the accumulation of the haplogroup
defining SNPs rather than a single mutation or private SNP.
Our findings are consistent with the sequencing results from
another cybrid study that used allelic discrimination and
Sanger sequencing to identify the mtDNA haplogroups (48).
The advancement of NGS for mtDNA analyses allowed deep
sequencing in ranges from 1,000 to 100,000 with an average
depth of 30,000 so that low level heteroplasmy could be reliably
identified. In addition, our method allowed for both strands of
mtDNA to be independently sequenced and in both directions,
which helps to distinguish between artifact and low level
heteroplasmy. The mechanisms of retrograde signaling for the
different mtDNA haplogroups are under investigation and likely
include as of yet unidentified pathways.
Comparison of GG Stretches Within the
MT-DLoop Region
Our previous report related to the MT-DLoop region showed
the greatest SNP variations in J vs. H mtDNA were in (a) the
nucleotides (np) 263–461 region; (b) Conserved Sequence Block
2 region (np 299-315); (c), H Strand Origin region (np 110-441);
(4) Hypervariable Segment 2 region (np 57-372); and (5) the
np 310–321 region that had high variability with C insertions
(48). However, H and J mtDNA had similar total numbers of
CpG and non-CpG methylation sites in the MT-DLoop. The
mtDNA is a target for epigenetic modifications and altered
methylation patterns have been associated with diseases, drug
exposure and aging (49–51). However, the degree of mtDNA
methylation is still controversial and some have suggested that
the methylation levels are very low to absent in mtDNA (52,
53). Cisplatin causes DNA damage by adduct formation at
intra-strand d(GpG) crosslink sites. The rate of DNA adduct
formation increases in acidic conditions (28, 54) and higher
numbers of GG stretches may lead to more binding of cisplatin
to the mtDNA. Importantly, our previous bioenergetic studies
showed that J cybrids preferentially use glycolysis and have higher
levels of extracellular acidification rates (ECAR) than the cybrids
with H haplogroup mtDNA (48), leading to the possibility
that the H and J mtDNA MT-DLoop may possess different
levels of GG sites. However, we found that within the MT-
Dloop regions, the numbers of GG stretches (GG, GGG, GGGG,
and GGGGG) were similar in H and J cybrids. Therefore, the
environmental microenvironment may be playing a bigger role
in cisplatin-related adduct formation rather than the numbers of
GG stretches in the mtDNA but further work is needed to clarify
this question.
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